PRO-RABEPRAZOLE TABLET (ENTERIC-COATED)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
05-09-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
RABEPRAZOLE SODIUM
Tillgänglig från:
PRO DOC LIMITEE
ATC-kod:
A02BC04
INN (International namn):
RABEPRAZOLE
Dos:
10MG
Läkemedelsform:
TABLET (ENTERIC-COATED)
Sammansättning:
RABEPRAZOLE SODIUM 10MG
Administreringssätt:
ORAL
Enheter i paketet:
10/100/500
Receptbelagda typ:
Prescription
Terapiområde:
PROTON-PUMP INHIBITORS
Produktsammanfattning:
Active ingredient group (AIG) number: 0143681001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2023-07-10
Produktens egenskaper
PRODUCT MONOGRAPH
PR
PRO-RABEPRAZOLE
Rabeprazole Sodium Enteric-Coated Tablets
10 mg and 20 mg
H
+
,
K
+
-ATPASE INHIBITOR
DATE OF REVISION:
September 5, 2019
PRO DOC LTÉE
2925, boul. Industriel,
Laval, Quebec
H7L 3W9
_Control #: 230299_
Rabeprazole pm en
Pg. 1
_PRO-RABEPRAZOLE Product Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
................................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................24
DETAILED PHARMACOLOGY
.......................................
Läs hela dokumentet
